A practical approach to relapsed multiple myeloma

Joseph R Mikhael

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. However, despite the addition of several novel agents, unprecedented response rates, and our ability to achieve complete remission in the majority of patients, the disease remains incurable in nearly all and will require repeated therapies. With many options available to the clinician, there is no simple or ideal sequence of treatments that has been established, so the choice of relapsed therapy is based on a series of factors that include response and tolerability of prior therapies, risk status, available novel agents, aggressiveness of relapse, renal function, performance status, cost, etc. This chapter provides practical guidance in selecting relapsed therapies structured through a series of 5 questions that can inform the decision. Specific emphasis is placed on the 2 most recent novel agents, carfilzomib and pomalidomide, but agents in development are also included.

Original languageEnglish (US)
Pages (from-to)262-267
Number of pages6
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Volume2014
Issue number1
DOIs
StatePublished - Dec 5 2014

Fingerprint

Multiple Myeloma
Therapeutics
Transplantation
Kidney
Costs and Cost Analysis
Recurrence
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

A practical approach to relapsed multiple myeloma. / Mikhael, Joseph R.

In: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, Vol. 2014, No. 1, 05.12.2014, p. 262-267.

Research output: Contribution to journalArticle

@article{48a5719bcf144cb4bd70a1bb9cccccac,
title = "A practical approach to relapsed multiple myeloma",
abstract = "There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. However, despite the addition of several novel agents, unprecedented response rates, and our ability to achieve complete remission in the majority of patients, the disease remains incurable in nearly all and will require repeated therapies. With many options available to the clinician, there is no simple or ideal sequence of treatments that has been established, so the choice of relapsed therapy is based on a series of factors that include response and tolerability of prior therapies, risk status, available novel agents, aggressiveness of relapse, renal function, performance status, cost, etc. This chapter provides practical guidance in selecting relapsed therapies structured through a series of 5 questions that can inform the decision. Specific emphasis is placed on the 2 most recent novel agents, carfilzomib and pomalidomide, but agents in development are also included.",
author = "Mikhael, {Joseph R}",
year = "2014",
month = "12",
day = "5",
doi = "10.1182/asheducation-2014.1.262",
language = "English (US)",
volume = "2014",
pages = "262--267",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - A practical approach to relapsed multiple myeloma

AU - Mikhael, Joseph R

PY - 2014/12/5

Y1 - 2014/12/5

N2 - There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. However, despite the addition of several novel agents, unprecedented response rates, and our ability to achieve complete remission in the majority of patients, the disease remains incurable in nearly all and will require repeated therapies. With many options available to the clinician, there is no simple or ideal sequence of treatments that has been established, so the choice of relapsed therapy is based on a series of factors that include response and tolerability of prior therapies, risk status, available novel agents, aggressiveness of relapse, renal function, performance status, cost, etc. This chapter provides practical guidance in selecting relapsed therapies structured through a series of 5 questions that can inform the decision. Specific emphasis is placed on the 2 most recent novel agents, carfilzomib and pomalidomide, but agents in development are also included.

AB - There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. However, despite the addition of several novel agents, unprecedented response rates, and our ability to achieve complete remission in the majority of patients, the disease remains incurable in nearly all and will require repeated therapies. With many options available to the clinician, there is no simple or ideal sequence of treatments that has been established, so the choice of relapsed therapy is based on a series of factors that include response and tolerability of prior therapies, risk status, available novel agents, aggressiveness of relapse, renal function, performance status, cost, etc. This chapter provides practical guidance in selecting relapsed therapies structured through a series of 5 questions that can inform the decision. Specific emphasis is placed on the 2 most recent novel agents, carfilzomib and pomalidomide, but agents in development are also included.

UR - http://www.scopus.com/inward/record.url?scp=84937553113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937553113&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2014.1.262

DO - 10.1182/asheducation-2014.1.262

M3 - Article

VL - 2014

SP - 262

EP - 267

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -